Table 1_Dysregulated fibroblast–immune crosstalk drives statin-associated erectile dysfunc

26.4 KB of research findings on the link between statin therapy and erectile dysfunction. The study by Yang Zhang, last updated in April 2026, integrates pharmacovigilance data, network pharmacology, and single-cell RNA sequencing analysis to identify key molecular mediators and cellular interactions.

Use Cases

• Identify drug-associated adverse events based on disproportionality analysis results for atorvastatin and rosuvastatin.
• Study fibroblast-immune cell crosstalk in disease based on single-cell RNA sequencing findings described in the results.
• Validate potential drug targets like FGFR1 and SERPINE1 using the molecular docking and dynamics simulation results mentioned.
• Analyze gene expression patterns in erectile dysfunction samples based on the transcriptomic and RT-qPCR validation described.

Strengths

• Integrates multiple analysis methods: pharmacovigilance, network pharmacology, toxicology, and single-cell RNA-seq.
• Identifies specific statins (atorvastatin, ROR=3.36; rosuvastatin, ROR=3.22) and four key genes (FGFR1, SERPINE1, TGFB2, TGFBR2) with supporting statistical evidence.
• Includes molecular docking and dynamics simulations demonstrating stable binding between atorvastatin and FGFR1.

Limitations

• The dataset is a 26.4 KB DOCX file, which is a very small document likely containing summary results rather than raw data tables.
• Row count and column-level documentation are unknown, limiting suitability assessment for direct computational analysis.
• Description metadata is limited; actual data quality and structure require manual inspection after download.

Provenance

Source

figshare, author Yang Zhang.

Collection Method

Integrative strategy merging real-world pharmacovigilance, network pharmacology, toxicological analyses, and single-cell RNA sequencing.

Freshness

Last updated 2026-04-28 09:53:39; freshness should be verified.